Variant of ETV6/ABL1 Gene Is Associated with Leukemia Phenotype

The ETV6/ABL1 fusion transcript is thought to be a very rare aberration in hematopoietic malignancies. We describe two new cases of acute leukemia with the ETV6/ABL1 fusion, acute myeloid leukemia with eosinophilia (case 1) and B acute lymphoblastic leukemia (ALL) (case 2), screened by multiplex RT-PCR. The ETV6/ABL1 fusion was also confirmed by fluorescence in situ hybridization using a mixture of BCR/ABL1 and ETV6/RUNX1 probes. A thorough review of all published cases showed that all 7 reported ALL patients possess the type A ETV6/ABL1 fusion transcript, composed of the first 4 exons of ETV6 fused to the second exon of ABL1. The presence of the type A fusion transcript strongly implies ALL manifestation in ETV6/ABL1-positive hematologic malignancies as minor BCR breakpoint in BCR/ABL1-positive ALL.

[1]  Li-li Wang,et al.  Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia , 2012, Annals of Hematology.

[2]  R. Marschalek,et al.  Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: Poor prognosis and prenatal origin , 2010, Genes, chromosomes & cancer.

[3]  C. Bredeson,et al.  Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. , 2009, Leukemia research.

[4]  A. Meloni-Ehrig,et al.  Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. , 2009, Cancer genetics and cytogenetics.

[5]  Joonhong Park,et al.  Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. , 2009, Cancer genetics and cytogenetics.

[6]  S. Ogawa,et al.  Chronic phase of ETV6‐ABL1 positive CML responds to imatinib , 2008, Genes, chromosomes & cancer.

[7]  J. Falkenburg,et al.  Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. , 2008, Cancer genetics and cytogenetics.

[8]  C. Chabannon,et al.  A fifteen‐year cytogenetic remission following interferon treatment in a patient with an indolent ETV6‐ABL positive myeloproliferative syndrome , 2007, American journal of hematology.

[9]  R Nyga,et al.  The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation , 2007, Oncogene.

[10]  O. Bernard,et al.  Activation of the NF-κB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKα , 2006, Oncogene.

[11]  A. Gratwohl,et al.  Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript , 2005, Leukemia.

[12]  J. Moore,et al.  Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. , 2005, Cancer genetics and cytogenetics.

[13]  R. V. van Etten,et al.  A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase , 2004, Molecular and Cellular Biology.

[14]  S. Scherer,et al.  Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia , 2003, Genes, chromosomes & cancer.

[15]  A. Barbouti,et al.  Clinical and genetic studies of ETV6/ABL1‐positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate , 2003, British journal of haematology.

[16]  Y. Keung,et al.  Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. , 2002, Cancer genetics and cytogenetics.

[17]  J. Aster,et al.  The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. , 2002, Blood.

[18]  J. Melo,et al.  Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. , 2002, Blood.

[19]  J. Rowley,et al.  Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping , 2001, Genes, chromosomes & cancer.

[20]  J. Griffin,et al.  ARG tyrosine kinase activity is inhibited by STI571. , 2001, Blood.

[21]  P. Marynen,et al.  Molecular cytogenetic and clinical findings in ETV6/ABL1‐positive leukemia , 2001, Genes, chromosomes & cancer.

[22]  S. Bohlander.  Fusion genes in leukemia: an emerging network , 2001, Cytogenetic and Genome Research.

[23]  L. Wiedemann,et al.  Haemopoietic transformation by the TEL/ABL oncogene , 1998, British journal of haematology.

[24]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[25]  M. Höglund,et al.  BCR/ABL‐negative chronic myeloid leukemia with ETV6/ABL fusion , 1997, Genes, chromosomes & cancer.

[26]  T. Golub,et al.  p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. , 1996, Oncogene.

[27]  T. Golub,et al.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia , 1996, Molecular and cellular biology.

[28]  O. Bernard,et al.  Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. , 2006, Oncogene.

[29]  P. Pelicci,et al.  Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. , 2002, Haematologica.

[30]  M. Andreeff,et al.  Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient , 2002, Leukemia.

[31]  L. Wiedemann,et al.  The novel activation of ABL by fusion to an ets-related gene, TEL. , 1995, Cancer research.

[32]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .